VERACYTE, INC.

Based in South San Francisco, Veracyte is a molecular diagnostics company that develops genomic classifiers for cancer detection and prognosis across multiple tumor types. The company's diagnostic tests analyze patient samples using genomic sequencing and molecular analysis to assess cancer risk and inform treatment decisions. Its primary product portfolio includes Afirma for thyroid nodule classification, Decipher for prostate and bladder cancer assessment, Prosigna for breast cancer prognosis, and Percepta for lung cancer screening via nasal swab. The company also offers nCounter analysis system services, which provide gene expression analysis capabilities.

Veracyte operates primarily through its molecular diagnostics business, with revenue generated from laboratory-developed test (LDT) services. Tests are performed in the company's CLIA-certified laboratory and sold through a direct sales model to healthcare providers, oncologists, and hospitals. The company serves the U.S. market as its primary geography, with international operations extending its reach to additional markets.

The company was incorporated in Delaware in 2006 and rebranded as Veracyte in 2008, having previously operated under the name Calderome, Inc. As a publicly traded entity on Nasdaq, the company maintains operations focused on expanding its genomic classifier portfolio and increasing test adoption among physicians managing cancer patients.